This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Encompass Health (EHC) Unveils Plans to Expand in Maryland
by Zacks Equity Research
Encompass Health's (EHC) plans to construct a hospital is indicative of the company's efforts to offer improved healthcare services in southern Maryland.
Universal Health (UHS) to Report Q4 Results: What to Expect?
by Zacks Equity Research
Universal Health's (UHS) fourth-quarter results are likely to reflect gain from better revenues.
MEDNAX's (MD) Q4 Earnings Fall Shy of Estimates, Tumble Y/Y
by Zacks Equity Research
MEDNAX's (MD) fourth-quarter results reflect muted revenues caused by the COVID-19 pandemic.
Community Health's (CYH) Q4 Earnings Surpass, Improve Y/Y
by Zacks Equity Research
Community Health's (CYH) fourth-quarter earnings gain from lower costs. However, the same is offset to some extent by soft admissions.
Is Tenet Healthcare (THC) a Great Value Stock Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
4 Hospital Stocks to Gain From Growth in Patient Admissions
by Sapna Bagaria
Players in the hospital industry are likely to gain from increasing patient admissions, government grants and cost-control measures.
Tenet Healthcare (THC) Q4 Earnings Beat Estimates, Rise Y/Y
by Zacks Equity Research
Tenet Healthcare's (THC) Q4 earnings improve on the back of better revenues.
What's in the Offing for Centene (CNC) This Earnings Season?
by Zacks Equity Research
Centene's (CNC) Q4 results are likely to reflect escalating costs and other COVID-related factors.
Tenet Healthcare (THC) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Tenet (THC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cigna (CI) to Report Q4 Earnings: What's in the Offing?
by Zacks Equity Research
Cigna's (CI) fourth-quarter results are likely to reflect strong performance across the business portfolio and lower SG&A costs, partly offset by continued COVID-19 related expenses.
Is Tenet Healthcare (THC) a Great Value Stock Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Top Ranked Momentum Stocks to Buy for February 1st
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, February 1st
Humana (HUM) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Humana's (HUM) fourth-quarter 2020 earnings might have endured escalating COVID-related expenses, partly offset by better revenues.
What's in the Cards for HCA Healthcare (HCA) Q4 Earnings?
by Zacks Equity Research
HCA Healthcare's (HCA) fourth-quarter earnings are likely to have witnessed better patient volumes and improved revenues.
Encompass Health (EHC) Q4 Earnings Beat Estimates, Rise Y/Y
by Zacks Equity Research
Encompass Health's (EHC) fourth-quarter results gain from improved revenues and lower costs, partly offset by lower volumes in both its segments.
Higher Testing to Aid Quest Diagnostics' (DGX) Q4 Earnings
by Zacks Equity Research
Within non-COVID base business, Quest Diagnostics (DGX) is expected to have secured higher returns in Q4 from the acquisitions of MACL, Memorial Hermann Outreach and Blueprint Genetics.
Anthem (ANTM) Q4 Earnings Miss Estimates, Revenues Up Y/Y
by Zacks Equity Research
Anthem's (ANTM) fourth-quarter results benefit from higher revenues stemming from robust Medicaid and Medicare businesses, partly offset by higher costs.
Boston Scientific (BSX) LOTUS Edge Recall to Mar Q4 Earnings
by Zacks Equity Research
Per Boston Scientific's (BSX) October update, it has started to see strong region-wise recovery.
Find 'Strong Buy' Stocks Near New Highs with this Screener
by Benjamin Rains
Why not look at stocks that have climbed along with the broader market and are trading near new highs...
Thermo Fisher (TMO) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
Thermo Fisher's (TMO) Life-Science Solutions and Specialty Diagnostics segments are expected to have contributed, banking on COVID-19-led growing healthcare needs.
Anthem (ANTM) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Anthem (ANTM) is likely to have witnessed increased revenues and a rise in membership during Q4, offset by an escalating expense level.
HCA Healthcare (HCA) Steps Up Efforts to Boost PPE Output
by Zacks Equity Research
HCA Healthcare (HCA) invests in new business to meet the buoyancy in demand for PPE and surgical masks.
Community Health (CYH) Unit Announces Junior Note Offerings
by Zacks Equity Research
Community Health's (CYH) wholly-owned arm exhibits monetary discretion by issuing notes to procure funds.
UnitedHealth (UNH) Q4 Earnings Top Estimates, Revenues up Y/Y
by Zacks Equity Research
UnitedHealth's (UNH) fourth-quarter results benefit from higher revenues and return of healthcare utilization to normalcy level, partly offset by higher costs.
Demand for COVID-19 Tests to Drive Abbott (ABT) Q4 Earnings
by Zacks Equity Research
Within EPD, Abbott (ABT) is expected to have witnessed visible signs of rebound through Q4.